Browse Category by Oncotarget
Health, Oncotarget

Warfarin-Like Drug Can Reverse Tamoxifen Defiance in Breast Cancer

Cancer is one of the diseases that is well known for evading treatment as well as developing resistance to drugs. Cancer-cells that are resistant to drugs and treatment are dangerous as they are able to spread throughout the patient’s body. This fact has become a huge challenge in the pursuit of getting a remission. This has been the case for breast cancer patients who are put under treatment using tamoxifen as they develop resistance to it. This makes the cancer to come back and consequently they are forced to use other drugs to attain remission. All this was revealed in a recent article published on Oncotarget. Read more about Oncotarget at Google Scholar.

Scientists Discovery

Scientists focused on finding out whether the tamoxifen resistance was closely associated with mitochondria. They found out that a protein, NQ01, triggers the decision in a cancer cell whether it survives the treatment or not. Michael P. Lisanti, MD, PhD. stated that the process of using tamoxifen in poisoning the cancerous cell brings about the opposite effect. This treatment method instead stimulates cancer cells to respond by way of revving their engines to ensure survival. The study further sought to find out the genes that are involved with the drug resistance. When the NQ01 was added to the cells, it allowed them to survive.

Findings

In order for this theory to be fool-proof, the cells that developed a resistance to tamoxifen were confronted with a NQ01 inhibitor. The drug used, dicoumarol, is also a vitamin K adversary just like warfarin. Using this inhibitor showed the reversal of the drug-resistant cancer cells. These new findings offer a ray of hope to breast cancer patients who show any signs of resistance to tamoxifen treatment.

About Oncotarget

Oncotarget refers to a global peer-reviewed journal that focuses mainly on different cancers, potential therapy targets as well as treatment protocols. It also focuses on the impact felt by management programs and new therapeutic protocols and agents on patients’ adherence, quality of life and satisfaction. The journal also seeks to explore the evidence brought forward to justify the fresh as well as existing therapies in improving the outcomes and defining their usage by the health care professionals and patients. The journal has an impact factor of 2.272 and for five years it stands at 2.235. Learn more about Oncotarget at researchgate.net

Oncotarget

Contributions of Mikhail Blagosklonny to Cancer Research and Anti-aging

Mikhail Blagosklonny holds a position as the chief editor of Cell Cycle and Oncotarget. He is an associate of other publications that focus on the treatment of cancer. He is known for his skills in therapy and biology of cancer. Mikhail is also on the editorial board of Cell Death and Differentiation. He is popular for his hypothesis in TOR which seeks to explore the relationship between cancer and aging. He has reportedly used Rapamycin on scimagojr.com to a carry out his research. Rapamycin is a popular drug used to treat cancer. Mikhail has shown a considerable zeal and approach to finding the latest approach to cancer therapy.

The longevity of cancer treatment research on Oncotarget has seen him become labeled as one of the most passionate advocates of the Rapamycin research. His research on Oncotarget varies from molecular biology, cellular biology to several clinical investigations. He has researched in other sections such as drug resistance of healthy cells, tumor suppressors, cell cycle, and anticancer therapeutics.

Blagosklonny has a thorough understanding of the field of medicine. He earned his Medical Doctorate in the field of internal medicine on msubmit.net. He later received a Ph.D. in the area of cardiology and medicine. He was able to attend the Russian Medical University and the First Pavlov Medical University. Blagosklonny’s experience in cancer research saw him become appointed as an associate professor of medicine at the New York Medical School. He held this position for some time in the year 2002 before earning a position as Senior Scientist at the Ordway Research Institute in Albany, New York. Blagosklonny was able to hold this position until 2009 before he became appointed as Professor of Oncology at the Roswell Park Institute of Cancer on impactjournals.com.

Blagosklonny has focused his research in the field of cancer and its therapies that protect cells from getting damaged. He is famous for his studies in the area of aging and coming up with anti-aging drugs. During his research on Oncotarget, he was able to hypothesize the working of the Rapamycin enzyme. The enzyme is popularly acclaimed for its positive effects in cancer treatment. He was able to see how the drug prolonged the lives of cells and therefore prevented aging.